PharmaLectures.com

Courses › Pharma training by line of business › Europe playbook for the biologics and biosimilars maker: licences, documents, customers, cost

Europe playbook for the biologics and biosimilars maker: licences, documents, customers, cost

Send your biologic dossier to Europe once and keep the review clock running.

  • 12 audio modulesthree lengths each
  • 2 h to 10 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Biologics and biosimilarswho it is written for

Why this training matters

On day 120 the European Medicines Agency sends a list of questions: your comparability data lack an assay the rapporteur expected. The clock stops. Your launch date moves, the manufacturing slot you booked sits empty, and a rival's hospital tender closes before you can bid.

What changes after this course

Your team files Common Technical Documents that answer the reviewer's questions before they are asked, and checks its own manufacturing data against EudraLex Volume 4 first. You hold a certificate per learner and a training record per person for your compliance files.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

Your regulatory team opens the Common Technical Document and knows which module each reviewer reads first. Module 1 forms are right, Module 3 puts the active substance data where the European Medicines Agency looks for it, and Modules 2, 3 and 5 do not contradict each other. The legal basis, Article 8(3) or Article 10(4) of Directive 2001/83/EC, is settled in one meeting.

Quality assurance specialists check the manufacturing section against EudraLex Volume 4 and Annex 2 before the inspector does. When the batch record and the dossier describe a step differently, they catch it at their desk. The answer to the inspector's question about process validation is already in the file.

Clinical leads size the comparative study to the European Medicines Agency biosimilar guidelines and the International Council for Harmonisation structure, with the comparability data in hand. The Clinical Overview names its own weak points first. When an assay differs from the reference product, the team knows what to say and what to run.

After approval, the team files Type IA and Type IB variations under Commission Regulation (EC) No 1234/2008 without calling a consultant to classify each change. Market access planners hand Health Technology Assessment bodies the comparative value evidence they ask for, and launch country by country as stock allows.

Who needs this training

  • Regulatory Affairs Manager

    The days before submission, when the Module 1 forms, Module 3 and the Clinical Overview must agree with each other, and one mismatch can stop validation.

  • Clinical Development Lead

    The meeting where you decide whether the comparability data support a reduced clinical programme or whether the agency will ask for another trial.

  • Quality Assurance Specialist

    The day an inspector asks how your process validation data support the dossier, and the answer has to come from the file, not from memory.

  • Market Access Strategist

    The first payer submission, when a Health Technology Assessment body asks for comparative value evidence that your registration trial was never designed to produce.

  • Project Manager, Biologics

    The planning meeting where the approval date, the clock stops and the first national launch must sit on one timeline alongside supply chain readiness.

Roles: Owner, CEO and board, Business development and export sales, Regulatory affairs

Businesses: Biologics and biosimilars

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Decide whether a biologic must use the centralized procedure and name the legal basis that fits it.
  2. Check a Common Technical Document across Modules 1, 2, 3 and 5 and find contradictions before validation does.
  3. Compare a batch record with the dossier and EudraLex Volume 4 and list the gaps an inspector would raise.
  4. Draft a Clinical Overview that states benefit, risk and known limits in the order a rapporteur reads them.
  5. Build a 210-day review calendar that marks each clock stop and the answers due at each one.
  6. Classify a post-approval change as Type IA, Type IB or Type II and prepare the matching filing.
  7. Prepare a clinical value summary for a Health Technology Assessment body and set a launch order for each country.

What the company gets

  • A dossier that reaches validation without avoidable administrative errors, so your review starts on the date you planned.
  • A manufacturing site team that can show an inspector how the batch record, the process validation data and the dossier match.
  • A straight, documented answer for payers and patient organizations when they ask what your biologic adds.
  • A launch plan that waits for the European Commission decision and for supply readiness instead of guessing the date.
  • A certificate per learner and a training record per person, ready for the next audit of your compliance files.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 12 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing2 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard5 h25 min a module, for regulatory, quality and business-development staff
Expanded10 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing2 h
Business development and export salesBriefing2 h
Regulatory affairsStandard5 h

Course outline: 12 modules

12 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Confirm your biologic must go through the centralized procedure

    • Why a biotechnology-derived product has no choice of route, and what that does to your plan.
    • How to read the annex of Regulation (EC) No 726/2004 and settle your route in one meeting.
    • Why the Committee for Medicinal Products for Human Use opinion is not yet the day you can ship.
  2. 2Choose the correct legal basis for your biologic's application

    • How to choose between a full dossier and the Article 10(4) biosimilar route before you plan studies.
    • What to do when your product is close to a reference product but not close enough to be called similar.
    • The reference product choice that holds when the agency asks what you compared against.
  3. 3Build a Common Technical Document that passes initial validation

    • Why one wrong form in Module 1 sends your dossier back before any scientist reads it.
    • How to lay out Module 3 so the reviewer finds the active substance data on the first try.
    • The cross-references between Modules 2, 3 and 5 that contradict each other and cost you validation.
  4. 4Align your manufacturing data with EudraLex Volume 4

    • How to show your inspector that your process validation data match what the dossier claims.
    • Which part of Annex 2 on biological active substances your site team must be able to defend.
    • What to do when the batch record and the dossier describe the same step in different words.
  5. 5Write a Clinical Overview that summarizes efficacy and safety

    • How to write the Clinical Overview so the benefit and risk argument is clear in the first pages.
    • The efficacy and safety gaps you should name yourself, before the rapporteur does.
    • When existing nonclinical data carry your case and when a reviewer will ask for new studies.
  6. 6Prove biosimilarity without inviting requests for more clinical trials

    • Why the quality comparison, not the clinical trial, carries most of your biosimilarity case.
    • How to size a comparative efficacy study so it answers the question and no more.
    • What to do when one assay shows a difference from the reference product.
  7. 7Map the 210-day review and plan for each clock stop

    • The two points where the clock stops and what you must have drafted before each one.
    • How to use the pre-submission meeting to lock the submission date and the dossier format.
    • Why a fast, complete answer to the Day 120 questions protects your opinion date.
  8. 8File Type IA and Type IB variations without stalling updates

    • How to tell whether a change is Type IA, Type IB or Type II before you build the file.
    • When a manufacturing change is a Type IA notification and when it is not.
    • The Summary of Product Characteristics edits that push a simple filing into Type II.
  9. 9Prepare clinical value data for Health Technology Assessment bodies

    • Why Health Technology Assessment bodies ask for evidence your registration trial never collected.
    • How to present comparative value so a payer can read it without a regulatory background.
    • The pricing and evidence questions to settle country by country before the first submission.
  10. 10Answer patient organizations and national agencies on the spot

    • How to reply to a patient organization question without promising more than the label allows.
    • What to do when a national competent authority inspector arrives for a pre-approval visit.
    • The patient experience points that make your unmet medical need argument stand up.
  11. 11Spot missing quality data before the European Medicines Agency does

    • Why an incomplete comparability dataset turns into a formal question during review.
    • How to format answers so the rapporteur can close each question instead of asking again.
    • The manufacturing gaps that bring an inspector to your site before approval.
  12. 12Sequence national launches to match your supply chain readiness

    • How to order your country launches so the first hospital order does not outrun your stock.
    • The post-marketing data to start collecting on day one of the launch.
    • How your local sales team quotes the Summary of Product Characteristics in a hospital tender.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

12 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 2 h in the briefing length and 10 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Biologics and biosimilars. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 108 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team